42,540 Shares in Galectin Therapeutics Inc. (NASDAQ:GALT) Acquired by Kovitz Investment Group Partners LLC

Kovitz Investment Group Partners LLC bought a new position in Galectin Therapeutics Inc. (NASDAQ:GALT) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 42,540 shares of the company’s stock, valued at approximately $117,000. Kovitz Investment Group Partners LLC owned approximately 0.07% of Galectin Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in the business. Marshall Wace LLP acquired a new stake in shares of Galectin Therapeutics during the 2nd quarter worth approximately $43,000. Rhumbline Advisers acquired a new stake in Galectin Therapeutics in the second quarter worth $44,000. Gladstone Institutional Advisory LLC bought a new stake in Galectin Therapeutics in the third quarter valued at $60,000. Traynor Capital Management Inc. raised its holdings in shares of Galectin Therapeutics by 23.5% during the second quarter. Traynor Capital Management Inc. now owns 42,871 shares of the company’s stock valued at $97,000 after purchasing an additional 8,164 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in shares of Galectin Therapeutics during the 2nd quarter worth about $146,000. 11.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently commented on GALT. StockNews.com raised Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Galectin Therapeutics in a research report on Friday, November 15th.

Galectin Therapeutics Price Performance

Shares of NASDAQ GALT opened at $2.11 on Friday. The company has a 50-day moving average price of $2.59 and a 200-day moving average price of $2.52. The stock has a market capitalization of $132.42 million, a P/E ratio of -2.89 and a beta of 0.69. Galectin Therapeutics Inc. has a 1 year low of $1.56 and a 1 year high of $4.27.

Galectin Therapeutics Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.